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Abstract
Central nervous system (CNS) tumors are categorized and graded for clinical and research 
purposes according to the World Health Organization (WHO) scheme which segregates tumors by 
histological type and predicted biological behavior. However, reporting of WHO grade in 
pathological reports is inconsistent despite its collection in cancer registration. We studied the 
completeness, concordancy, and yearly trends in the collection of WHO grade for primary CNS 
tumors between 2004 and 2011. Data from the Surveillance, Epidemiology and End Results 
program were analyzed for the percentage of histologically diagnosed primary CNS tumor cases 
with concordantly documented WHO grades between 2004 and 2011. Yearly trends were 
calculated with annual percentage changes (APC) and 95 % confidence intervals (95 % CI). 
Completeness and concordancy of the collection of WHO grade varied significantly by 
histological type and year. The percentage of cases with documented WHO grade increased 
significantly from 2004 to 2011: 39.0 % of cases in 2004 had documented WHO grade, while 77.5 
% of cases had documented grade in 2011 (APC, 10.3; 95 % CI: 9.0, 11.5). Among cases with 
documented WHO grade, the percentage graded concordantly increased significantly from 89.1 % 
in 2004 to 93.7 % in 2007 (APC, 1.8; 95 % CI: 1.0, 2.6) and these values varied over time by 
histological type. One common trend among all histologies was a significant increase in the 
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percentage of cases with documented WHO grade. A sizeable proportion of reported CNS tumors 
collected by cancer registrars have undocumented WHO grade, while a much smaller proportion 
are graded discordantly. Data collection on grade has improved in completeness and concordancy 
over time. Efforts to further improve collection of this variable are essential for clinical care and 
the epidemiological surveillance of CNS tumors.
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Introduction
There are over 100 histologically distinct types of primary central nervous system (CNS) 
tumors, each with its own spectrum of clinical presentations, treatments, and outcomes. The 
first edition of the World Health Organization (WHO) Classification of Tumours of the 
Central Nervous System was published in 1979 as a unifying system for classifying CNS 
tumors [1]. It has been revised three times, most recently in 2007 [2–4], and has become the 
international standard for the categorization of CNS tumors. The WHO classification system 
acts as a common language for communication between clinical and basic science 
investigators worldwide [5–7].
Unlike most other cancers, CNS neoplasms are not staged and, therefore, grading takes on a 
heightened importance for patient management [8]. Grading assignment is achieved through 
the WHO classification system which provides a grading scheme in order to indicate 
predicted clinical behavior based on morphologic features (WHO grade I–IV) [5, 7]. As 
such, the WHO grade often estimates clinical outcomes and guides the management of some 
CNS tumors [5, 6]. Updates to WHO classification and grading result in improved 
correlations between histological grade and outcomes and can affect changes in diagnostic 
and clinical practice [7, 9]. WHO grading is also used in population and epidemiological 
studies to identify patterns of diagnosis for CNS tumors. For example, a substantial change 
from the 1993 to 2000 WHO classification and grading scheme for meningiomas resulted in 
an increase in the frequency of diagnosis and thus the incidence of grade II meningiomas, a 
tumor which carries a poorer prognosis than grade I meningiomas [10].
However, despite its clinical and epidemiological use, reporting of WHO grade remains 
optional in both pathology reports and cancer registration [5, 6]. The College of American 
Pathologists (CAP) recommends, but does not require, that WHO grade be assigned in 
pathological reports [8]. Grading is also not a required item by either of the two major 
cancer registry programs in the United States: the Centers for Disease Control and 
Prevention’s (CDC) National Program of Cancer Registries (NPCR) and the National 
Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) program.
A previous study by Kruchko, et al. analyzed the completeness and concordancy of WHO 
grading for primary CNS tumor cases from 2004 to 2008 within 18 SEER cancer registries 
and revealed a substantial frequency of undocumented or discordant WHO grades [11]. The 
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objective of this report is to expand and update this analysis by describing the completeness, 
concordancy and trends in the collection of WHO grade for primary CNS tumor cases from 
2004 to 2011 using SEER data.
Materials and methods
Data collection
This study used data from the SEER program of the NCI, which includes ~28 % of cancer 
cases for the US population [12]. Specifically, the SEER 18 Registries Research Data set 
(Nov 2013 submission) containing data updated to year 2011 was used [13]. Non-malignant 
tumors were also included in this analysis. 2004 was selected as the start year of this study 
since the collection of these tumors was initiated on January 1, 2004. Adoption of this 
practice was the direct result of the passage of the Benign Brain Tumor Cancer Registries 
Amendment Act (Public Law 107–260) which mandated that all non-malignant CNS tumors 
be registered within the United States [14, 15]. In addition, WHO grade which is recorded in 
the SEER cancer registry as Collaborative Stage Site Specific Factor 1 [16] was available 
from 2004 and onward [13]. For these reasons, primary years of analysis were from 2004 to 
2011.
Regarding cancer registration guidelines for WHO grade, SEER records WHO grade based 
on instructions from the Collaborative Stage Data Collection Manual [15] which states that 
WHO grade is recorded from a pathology report; WHO grade is not recorded if the 
diagnosis is made radiographically [16]. Information from the pathology report is first 
recorded by tumor registrars from treatment centers and cancer care programs who then send 
this information to central (state) cancer registries who submit it to SEER [17]. Tumor 
registrars and central cancer registries are held under quality controls checks to ensure that 
the information reported to SEER is as accurate and complete as possible.
Primary CNS tumors were identified for WHO grade analysis based on the International 
Classification of Diseases for Oncology, 3rd edition (ICD-O-3) site codes (C70.0–72.9, 
C75.1–75.3) [15]. CNS tumor groups were selected based on their overall incidence over the 
time period and by clinical interest [11] and listed according to ICD-O-3 histology and 
behavior codes (Table 2). Since the histology and grade of CNS tumors are more accurately 
determined when they are microscopically confirmed, this study primarily focused on cases 
with microscopic (e.g. histopathologic) confirmation [17, 18]. Cases in which the 
histological diagnosis is assigned without microscopic confirmation, such as those identified 
radiographically without surgical resection and which are also reported to cancer registries, 
were included but not the focus of this study. Designated WHO grades for specific 
histological types were based on the 2007 WHO grading scheme [5] and did not differ 
substantially from the 2000 grading scheme for these selected histologies [7].
Statistical analysis
SEER*Stat 8.1.5 statistical software (http://seer.cancer.gov/seerstat) was used to generate 
counts and proportions to analyze completeness, concordancy, and time trends of WHO 
grading. Completeness of WHO grade was determined by the percentage of tumor cases 
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with documented WHO grade (I–IV). Cases in which WHO grade was not assigned, was 
assigned but not documented in the pathology report, or was assigned, documented, but not 
recorded within cancer registries were classified as cases with undocumented WHO grade. 
Concordancy was determined by the percentage of tumor cases with a documented WHO 
grade and with concordant grading in relation to the WHO grading scheme, which directly 
assigns each specific histological diagnosis with a defined WHO grade. For example, the 
WHO grading scheme directly assigns tumors with a histological diagnosis of pilocytic 
astrocytoma as a grade I tumor and so pathological reports for this tumor with a grade I were 
deemed concordant, and reports with grades II, III, IV were deemed discordant. Thus, the 
grade is determined to be concordant if the pathologist assigned a WHO grade for a specific 
histological diagnosis that corresponds with the WHO grading scheme. Time trends in data 
collection for WHO grade were determined by tracking these two variables between 2004 
and 2011. The Joinpoint Regression Program 4.1.1 (htttp://surveillance.-cancer.gov/
joinpoint/) was used to determine trends by calculating an annual percentage change (APC) 
and 95 % confidence interval (95 % CI).
Results
Overall WHO Grade completeness and concordancy
Completeness and concordancy of WHO grade were calculated for all selected histologies as 
a group (Table 1). From 2004 to 2011 there were a total of 86,080 cases, of which 57,480 
(66.8 %) were microscopically confirmed and 28,600 that were not (33.2 %). Among all 
tumor cases, 39.7 % had documented WHO grade, and 93.6 % of those with documented 
WHO grade were graded concordantly.
Among microscopically confirmed cases, 58.5 % had documented WHO grade, and 93.6 % 
of these cases with documented WHO grade were graded concordantly. Cases that were not 
microscopically confirmed had 1.9 % of cases with documented WHO grade of which 95.9 
% of these cases were graded concordantly. These included cases where the histological 
diagnosis was done radiographically, and a WHO grade was still recorded in the SEER 
registry. However, these cases were not further analyzed in regards to specific histologies or 
trends.
Histology-Specific WHO Grade completeness and concordancy
Selected histologic groups were analyzed individually for completeness and concordancy in 
WHO grade from 2004 to 2011 (Table 2). The percentage of microscopically confirmed 
tumor cases ranged from a low of 46.0 % for non-malignant meningioma to 100.0 % for 
anaplastic ependymoma.
Completeness of WHO grade varied by histological type. More than 80 % of all cases had 
grade documented for anaplastic astrocytoma, oligodendroglioma, anaplastic 
oligodendroglioma, and oligoastrocytoma/anaplastic oligoastrocytoma, whereas less than 25 
% of all cases had WHO grade documented for craniopharyngioma and hemangioblastoma.
Concordancy of WHO grade also varied based on histological type. Among cases that were 
graded, more than 98 % of craniopharyngioma and hemangioblastoma were graded 
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concordantly in contrast to anaplastic/malignant meningioma in which only 55.8 % were 
graded concordantly.
Time trends in WHO Grade completeness and concordancy
Yearly percentages of documented and concordant WHO grade were determined overall for 
microscopically confirmed CNS tumor cases for each year between 2004 and 2011 (Fig. 1). 
There was a significant decrease in the percentage of cases microscopically confirmed each 
year beginning with 71.9 % in 2004 and ending with 64.3 % in 2011 (APC, −1.6; 95 % CI 
−2.1, −1.1). Among specific histologies analyzed for yearly trends, non-malignant 
meningioma was the only histology that resulted in a significant decrease in the percentage 
of microscopically confirmed cases overtime. The percentage of cases with documented 
WHO grade significantly increased each year: 39.0 % of cases in 2004 had documented 
WHO grade, and in 2011, 77.5 % of cases had documented grade (APC, 10.3; 95 % CI 9.0, 
11.5). Among those with documented grade, the percentage of cases graded concordantly 
increased significantly from 2004 (89.1 %) to 2007 (93.7 %) (APC, 1.8; 95 % CI 1.0, 2.6). 
From 2007 to 2011 this percentage did not change significantly and remained stable at 
roughly 94 % (APC, 0.2; 95 % CI −0.3, 0.7).
Specific histologies were also analyzed for yearly trends in WHO grade between 2004 and 
2011 based on incidence and clinical interest. These included glioblastoma/giant cell 
glioblastoma/gliosarcoma, non-malignant meningioma, atypical meningioma, and 
anaplastic/malignant meningioma (Fig. 2). For glioblastoma/giant cell glioblastoma/
gliosarcoma, there was no significant change in the percentage of microscopically confirmed 
cases over time (APC, 0.3; 95 %CI 0.0, 0.5), but there were significant increases in the 
percentage of cases with documented WHO grade (APC, 7.2; 95 % CI 6.2, 8.2) and with 
concordant grades among those cases (APC 0.7; 95 % CI 0.4, 0.9). For non-malignant 
meningioma, there was a significant decrease in the percentage of cases being 
microscopically confirmed (APC, −3.1; 95 % CI −3.8, −2.5) and a significant increase in the 
percentage of cases with documented WHO grade (APC, 18.3; 95 % CI 13.8, 22.9). Among 
cases that had documented WHO grade, there was no significant change in the percentage of 
cases being graded concordantly between 2004 and 2006 (APC, 0.7; 95 % CI −1.0, 2.3), but 
this finding was followed by a significant decrease between 2006 and 2011 (APC, −0.6; 95 
% CI −0.9, −0.2). For atypical meningioma, there were significant increases in the 
percentage of microscopically confirmed cases (APC, 1.3; 95 %CI 0.2, 2.4) and in cases 
with documented WHO grade (APC, 11.8; 95 % CI 7.9, 15.8). However, there was no 
significant change in the number of cases being graded concordantly (APC, 0.5; 95 % CI 
−0.8, 1.8). Anaplastic/malignant meningioma followed a similar pattern. Between 2004 and 
2011, there were significant increases in the percentage of microscopically confirmed cases 
(APC, 2.9; 95 % CI 1.7, 4.2) and in cases with documented WHO grade (APC, 9.8; 95 % CI 
4.5, 15.4). However, there was no significant change in the number of cases being graded 
concordantly (APC, 3.8; 95 % CI −4.2, 12.4). These specific histologies displayed wide 
variability in time trends. However, one common trend observed among all four histologies 
(glioblastoma/giant cell glioblastoma/gliosarcoma, non-malignant meningioma, atypical 
meningioma, and anaplastic/malignant meningioma) was a significant increase in the 
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percentage of cases with documented WHO grade between 2004 and 2011. APCs and 95 % 
CIs for time trends are summarized in Table 3.
Discussion
A significant number of CNS tumor cases reported to SEER registries from 2004 to 2011 
had undocumented WHO grade; however, among cases that were graded, over 90 % were 
graded concordantly (Table 1). All CNS tumor types had cases with undocumented or 
discordantly assigned WHO grade, yet completeness and concordancy of WHO grading 
varied by histological type of tumor (Table 2).
The inclusion of WHO grade on pathology reports remains optional in the United States [5, 
6]. Although clinicians are using WHO grading in their practices, WHO grade may not be 
documented on pathological reports. Furthermore, according to the College of American 
Pathologists (CAP) guidelines, neuropathologists have options in reporting–including: 
choosing to assign a WHO grade, reporting grade as not applicable, reporting grade as 
cannot be determined, or not assigning a WHO grade–that may affect documentation and, 
therefore, further impede the registrar’s ability to consistently collect this variable [8].
Although the WHO Classification of Tumours of the Central Nervous System establishes a 
defined WHO grade for each histological diagnosis, neuropathologists make the final 
assignment of grades on a case by case basis [8] further complicating the documentation 
process. As a result, pathologists may choose to assign a WHO grade that deviates from the 
grading scheme (SEER registries record WHO grades based on the assignment of the 
working pathologist even if it deviates from the defined grading scheme [15]). Tumors with 
deviated WHO grade would, therefore, contribute to the number of cases determined to be 
discordantly graded. However, we found that, overall, most diagnosed tumors conform to 
the WHO grading scheme and so these cases probably only account for a small proportion 
[5]. Finally, one cannot dismiss that errors in cancer registration are also a possible cause for 
both undocumented and discordant WHO grades. For example, if a pathologist assigns a 
concordant WHO grade on a pathology report, recording of grade in the registries could 
have been overlooked or recorded erroneously resulting in a tumor case with an 
undocumented or discordant WHO grade within the SEER database.
Only a small portion of all CNS tumor cases between 2004 and 2011 were discordantly 
graded, as most were either undocumented or assigned the concordant WHO grade (Tables 
1, 2). In other words, the large majority of these cases either had no documented WHO 
grade or were graded concordantly. This may indicate that neuropathologists are more likely 
to leave a WHO grade unassigned in a pathology report than assign a discordant WHO grade 
as it may be difficult to assign grade for tumors with histological features that are 
problematic to interpret or do not readily fit into a definitive grade [19].
Microscopically confirmed cases had a higher proportion of documented WHO grade when 
compared to cases that were not microscopically confirmed (Table 1). Cases that were not 
microscopically confirmed (e.g. CNS tumors identified radiographically but did not result in 
surgery for histologic confirmation) had WHO grade documented in 1.9 % of the cases. This 
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finding most likely reflects the current practice in which WHO grade cannot be assigned for 
tumors that are diagnosed radiographically. Furthermore, many non-malignant CNS tumors 
may not receive surgery as their first course of treatment prohibiting microscopic (i.e. 
histopathologic) confirmation of their disease. These results reaffirm that microscopic 
confirmation is necessary for the assignment of histological type and grade for CNS tumors 
[17, 18].
Overall, from 2004 to 2011 an increasing proportion of cases each year were documented 
and assigned with the concordant WHO grade (Fig. 1). A factor which most likely 
contributed to the increase of documented and concordant WHO grade over time was the 
impetus in cancer centers to use a standardized protocol provided by the CAP in reporting 
the results of surgically biopsied or resected CNS tumors. This protocol was developed to 
assist pathologists in reporting useful and relevant information and consists of a checklist 
that specifies factors such as primary tumor site, histological diagnosis, and WHO grade [8]. 
WHO grade has been included in this protocol since its early versions before 2004 and the 
current version published in 2014 also includes the most updated WHO grading scheme as a 
reference for working pathologists. The rise in documented WHO grade may in part be 
explained by the mandate in January 1, 2004 by the Commission on Cancer (CoC), a 
program of the American College of Surgeons, for the use of the CAP protocol as part of its 
Cancer Program Standards for Approved Cancer Programs that allows for CoC accreditation 
which recognizes a cancer care program for comprehensive, high-quality patient centered 
care [8]. Current Cancer Program Standards for CoC accreditation requires that CAP 
protocol elements such as WHO grade are reported in at least 90 % of pathology reports. 
This mandate may have led to an increase in the number of treatment centers and cancer 
care programs seeking CoC accreditation to use the CAP protocol in pathology reports.
Time trends for specific histologies such as glioblastoma and non-malignant meningioma 
show that improvements over time in completeness and concordancy of WHO grade vary 
significantly based on histology (Fig. 2). Of particular note is the significant increase in the 
percentage of cases with documented WHO grades for grade I, II, and III meningiomas. This 
may reflect the changes in the 2000 WHO classification system in which the diagnosis of 
these tumors is correlated directly with grade and, therefore, contribute to making WHO 
grade documentation straightforward and reproducible [20]. Furthermore, these changes 
have helped clarify the determination of grade for the histological subtypes of meningioma, 
such as microcystic (grade I), chordoid (grade II), and papillary (grade III) meningiomas.
Variable trends in non-malignant meningioma (grade I), atypical meningioma (grade II), and 
anaplastic/malignant meningioma (grade III) most likely reflect changes in the diagnostic 
approach or classification of these tumors. The significant decrease in the percentage of 
cases with microscopic confirmation for non-malignant meningioma, the most common 
among the three types, may be the result of increased dependence or reliability on 
neuroimaging as the method of diagnosis for these tumors. Given that non-malignant 
meningioma accounts for an overwhelming majority of CNS tumor cases (Table 2), a 
decrease in the percentage of non-malignant meningiomas with microscopic confirmation 
would cause a significant decrease in the overall percentage of microscopically confirmed 
cases seen in CNS tumors over the years (Fig. 1). Yearly variability in the percentage of 
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cases with concordant grading for atypical and anaplastic/malignant meningioma most likely 
reflects the continuing difficulty in establishing a system that consistently and appropriately 
classifies and grades these tumors. Multiple studies have shown that reassessment of 
meningiomas based on updated WHO classification and grading criteria have led to the 
reclassification of histological diagnosis and grade for these tumors. For instance, a study in 
2006 by Simon, et al. studied the impact of the revised WHO 2000 classification system by 
analyzing 57 cases of meningioma that were previously classified and graded based on the 
WHO 1993 criteria [21]. They found that a significant number of cases previously 
diagnosed as atypical and anaplastic/malignant meningioma were classified and graded 
differently based on the WHO 2000 criteria in which the study suggested that more stringent 
criteria be established in the classification and grading of these tumors. A similar study by 
Yang, et al. in 2007 revealed parallel results [22] and another by Rosenberg, et al. in 2009 
stated that the WHO 2000 and 2007 definitions for grade III meningiomas classify a 
substantially different group of tumors when compared to previous definitions [23]. 
Difficulty in the classification and grading of meningiomas will continue to produce 
variations in the diagnosis, grading, and epidemiology of these tumors.
Differences in diagnostic, prognostic, or therapeutic approach may influence the application 
of WHO grade for individual histologies and account for the variability seen in WHO grade 
assignment (Table 2). For instance, WHO grade can be a consistent predictor of clinical 
outcomes for some but not all tumors. For certain tumors, other characteristics such as 
molecular markers may be better at predicting clinical outcomes and guiding management 
[19]. Tumors with a higher percentage of documented WHO grade most likely represent 
histologies in which grade has been found to be clinically useful for prognosis and 
therapeutic management. Additionally, for histologies with similar or overlapping names, 
WHO grade may be more frequently assigned because it can act as a safety check to insure 
that the appropriate histological diagnosis was made. For instance, the assignment of WHO 
grade II for oligodendroglioma on a pathology report would help differentiate it from 
anaplastic oligodendroglioma which is assigned a WHO grade III. For histologies in which 
the name is distinct and only a single WHO grade is assigned, such as craniopharyngioma, 
the grade is implied in pathology report diagnosis and so the assignment of WHO grade 
might be considered redundant in the clinical setting and thus grade would be less often 
documented. Continued investigations in identifying patterns of completeness and 
concordancy in documentation of WHO grade would be useful in further understanding its 
clinical use and in determining if certain CNS tumors warrant reassignment of grade or 
classification.
Overall, improvements in completeness and concordancy of WHO grading are being seen 
overtime and efforts to continue this trend should be made. Pathologists should continue to 
use standardized protocols such as those offered by the CAP to ensure more consistent 
collection of this variable. Programs such as the CoC that accredits cancer care programs 
and cancer registries should also set high standards for the collection of grade and other 
cancer related elements, such as newer molecular markers, as these will be important in 
epidemiological and research studies. Updates to the WHO classification and grading 
system that adapt to the growing body of knowledge revolving around CNS tumors are 
essential, as this system has become the standard by which the neuro-oncology community 
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diagnoses and grades tumors. By ensuring that grade accurately reflects tumor behavior and 
prognosis, clinicians will be more inclined to use it in their practices as a reliable indicator 
of patient outcomes, and thereby affecting its inclusion in the medical record and eventual 
collection by tumor registrars.
Strengths and limitations
This analysis provides important information on the use of WHO grade in clinical practice 
and the concordancy of its collection in a population-based cancer registry representing ~28 
% of brain and CNS tumor cases in the United States in a selected time period, 2004–2011.
An important limitation of this study is that, although quality control checks exist for cancer 
registries [17], there is no mechanism for central pathology review. Trained cancer registrars 
abstract information on WHO grade directly from pathology reports which represent the 
opinions of individual pathologists and may influence the number of cases with 
concordantly/discordantly assigned WHO grade in spite of our focus on microscopically 
confirmed cases.
Similarly, the lack of central pathology review implies that there is uncertainty in whether an 
error in the assignment of WHO grade versus the histological diagnosis was made in cases 
in which the grade was discordant for the given histology. In this study, the histological 
diagnosis assigned by the pathologist was assumed to be accurate in which concordancy of 
WHO grade was subsequently determined. Implementation of a central pathology review 
system at the level of individual treatment centers and their registrars, central cancer 
registries, and with SEER would encourage complete, accurate, and reliable collection of 
WHO grade along with other useful and relevant cancer elements such as histological 
diagnosis and molecular markers.
Based on current guidelines, WHO grade and histological diagnosis ideally should have 
been directly recorded from pathology reports. However, this may not always be the case 
and the SEER*Stat statistical program used for this analysis is unable to verify if recorded 
WHO grades or histological diagnoses were in fact directly abstracted from pathology 
reports. Thus, any errors in the recording of WHO grade or histology that would be present 
in the SEER database would also be present in this analysis. Microscopically confirmed 
cases were chosen to be analyzed because SEER guidelines place priority in using 
pathological reports to record the histological diagnosis and WHO grade for these cases.
The inability to identify the cause on why certain cases were recorded with an 
undocumented WHO grade within the SEER registry was also a limitation of this study. It 
would be interesting to explore these cases to determine if WHO grades are primarily 
undocumented within registries because they are not being assigned by pathologists or 
because of errors in cancer registration. Determining these patterns would help identify areas 
of improvement and strategies for the collection of WHO grade. A special study looking at 
individual records would be needed in order to investigate the collection of WHO grade 
from clinical records in order to provide a clear evaluation of collection practices.
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Conclusions
This study revealed that overall, primary CNS tumors reported to central cancer registries 
have a significant proportion of cases with undocumented WHO grade. For those cases with 
microscopic confirmation, even though discordant WHO grades were low, improvements in 
both the completeness and concordancy of WHO grading have been made over time. 
Neuropathologists and cancer registrars should continue their efforts to ensure that 
documentation of WHO grade is complete and concordant. The collection of this variable is 
important for cancer surveillance efforts and for performing a population-based calculation 
of clinical outcomes, as well as for clinical care and research purposes [20–23].
For clinicians and neuropathologists, assigning WHO grade holds significant clinical value 
for patient care in neuro-oncology. This is the case even in the context of testing for 
molecular markers which have currently been identified for several histologic types of CNS 
tumors and which will likely be used in combination with WHO grade to assign diagnosis 
and therapy, and to predict prognosis [6, 8, 19]. Along with histological identification, WHO 
grade will continue to provide important information for the prognosis and management of 
CNS tumors. For cancer surveillance, it is important that the collection of WHO grade 
continues to improve over time. Comprehensive and consistent inclusion of this variable in 
cancer databases helps to increase the clinical utility of cancer surveillance for population 
and epidemiological studies. Gaining a better understanding of trends of WHO grade 
collection in population-based registries may also prove useful in evaluating its application 
in clinical practices in the United States. Furthermore, this study provides documentation 
which may be useful to revisions of future grading schemes of the WHO Classification of 
Tumours of the Central Nervous System so that improved correlations between histological 
grade and outcomes continue to be made.
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Fig. 1. 
Percentage of cases that are microscopically confirmed (MC)a, MC with documented WHO 
gradeb, and MC with documented WHO grade and graded concordantlyc per year for all 
selected CNS tumors between 2004 and 2011 (SEER 18 Registries Research Data)
a% MC: (APC, −1.6; 95% CI: −2.1, −1.1)
b% MC with documented WHO grade: (APC, 10.3; 95% CI: 9.0, 11.5)
c% MC with documented WHO grade and graded concordantly: (2004–2007; APC, 1.8; 
95% CI: 1.0, 2.6), (2007–2011; APC, 0.2; 95% CI: −0.3, 0.7)
Lym et al. Page 13
J Neurooncol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 2. 
Percentage of cases that are microscopically confirmed (MC), MC with documented WHO 
grade, and MC with documented WHO grade and graded concordantly per year for selected 
CNS tumors between 2004 and 2011: Glioblastoma/Giant Cell Glioblastoma/Gliosarcomaa, 
Meningiomab, Atypical Meningiomac, Anaplastic/Malignant Meningiomad (SEER 18 
Registries Research Data)
a
,*Glioblastoma (9440/3), Giant Cell Glioblastoma (9441/3), Gliosarcoma (9442/3): % MC: 
(APC, 0.3; 95% CI: 0.0, 0.5); % MC with documented WHO grade: (APC, 7.2; 95% CI: 6.2, 
8.2); % MC with documented WHO grade and graded concordantly: (APC, 0.7; 95% CI: 
0.4, 0.9)
bMeningioma: % MC: (APC, −3.1; 95% CI: −3.8, −2.5); % MC with documented WHO 
grade: (APC, 18.3; 95% CI: 13.8, 22.9); % MC with documented WHO grade and graded 
concordantly: (2004–2006; APC, 0.7; 95% CI: −1.0, 2.3), (2006–2011; APC, −0.6; 95% CI: 
−0.9, −0.2)
cAtypical Meningioma: % MC: (APC, 1.3; 95% CI: 0.2, 2.4); % MC with documented 
WHO grade: (APC, 11.8; 95% CI: 7.9, 15.8); % MC with documented WHO grade and 
graded concordantly: (APC, 0.5; 95% CI: −0.8, 1.8)
dAnaplastic/Malignant Meningioma: % MC: (APC, 2.9; 95% CI: 1.7, 4.2); % MC with 
documented WHO grade: (APC, 9.8; 95% CI: 4.5, 15.4); % MC with documented WHO 
grade and graded concordantly: (APC, 3.8; 95% CI: −4.2, 12.4)
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Table 1
Aggregated percentages for all selected CNS tumors classified by WHO grade (Collaborative Site Specific 
Factor 1) and microscopically confirmed from 2004 to 2011 (SEER 18 registries research data)
Total counts Documented WHO
grade (%)
Documented WHO grade and graded
concordantly (%)
Microscopically confirmed 57,480 33,639 (58.5) 31,490 (93.6)
Not microscopically confirmed 28,600 555 (1.9) 532 (95.9)
Total 86,080 34,194 (39.7) 32,022 (93.6)
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